Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by SunTrust Banks Inc. from a “reduce” rating to a “neutral” rating in a research report issued on Wednesday.

Other equities research analysts have also issued reports about the stock. Piper Jaffray Cos. reaffirmed a “sell” rating and set a $6.00 price target on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Wedbush reaffirmed a “neutral” rating and set a $14.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, May 25th. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Finally, Robert W. Baird reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $35.35.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 93.96% during midday trading on Wednesday, reaching $54.60. 39,103,514 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $26.16 and its 200 day moving average price is $20.47. The firm’s market cap is $2.62 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $56.18.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the company earned ($0.87) EPS. Equities research analysts anticipate that Sarepta Therapeutics will post ($5.16) EPS for the current year.

In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $154,000. Quantitative Systematic Strategies LLC purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $211,000. National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.